PaxMedica's CEO and Malawi Health Official Discuss Urgent Medical Crisis in Bell2Bell Podcast
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 26 2024
0mins
Should l Buy ?
Source: newsfilter
- PaxMedica Podcast Episode: PaxMedica, a biopharmaceutical company, featured in the latest episode of The Bell2Bell Podcast discussing their response to an urgent medical request from Malawi.
- PaxMedica's Medical Assistance: PaxMedica addresses the critical shortage of medications needed for treating sleeping sickness crisis in Malawi, focusing on providing IV suramin (PAX-101).
- IBN's Commitment: IBN reinforces its commitment to expanding its network of brands and client partners through The Bell2Bell Podcast and the IBN Podcast Series.
- About PaxMedica: PaxMedica is a clinical-stage biopharmaceutical firm specializing in anti-purinergic drug therapies for neurological disorders, including Autism Spectrum Disorder (ASD).
- IBN Services: IBN offers various services like wire solutions via InvestorWire, article syndication, press release enhancement, social media distribution, corporate communications solutions, and news coverage solutions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
